Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;44(18):1300-1311.
doi: 10.1038/s41388-025-03306-2. Epub 2025 Feb 18.

The role of miR-92b-3p in notch signaling and monitoring of oral squamous cell carcinoma

Yudan Piao  1   2 , Seung-Nam Jung  3 , Mi Ae Lim  3 , Sicong Zheng  2 , Chan Oh  2 , Yan Li Jin  2 , Shan Shen  2 , Quoc Khanh Nguyen  2 , Se-Hee Park  2 , Young Il Kim  4 , Min-Gyu Kim  5 , Ji Won Kim  6 , Sun Ohm  7 , Jae Won Chang  2   3 , Ho-Ryun Won #  8   9 , Bon Seok Koo #  10   11
Affiliations

The role of miR-92b-3p in notch signaling and monitoring of oral squamous cell carcinoma

Yudan Piao et al. Oncogene. 2025 May.

Abstract

Dysregulation of microRNAs (miRNAs) influences diverse hallmarks of cancer, including proliferative signaling, metastasis, and resistance to cell death. We explored the contribution of miR-92b-3p in oral squamous cell carcinoma (OSCC) and its potential as a monitoring biomarker. Analysis of TCGA, GEO, and our own cohort revealed dysregulation of miR-92b-3p in OSCC, which correlated with aggressive tumor characteristics. miR-92b-3p overexpression augmented proliferation and the epithelial-mesenchymal transition in both YD8 and SCC25 cell lines and xenograft models. Mechanically, augmented miR-92b-3p expression suppressed ATXN1 and CPEB3, activating the Notch signaling pathway and thereby promoting metastasis and cisplatin resistance. In our cohort, serum miR-92b-3p expression reflected the disease status, including relapse. Our results suggest that miR-92b-3p might be an onco-miR involved in OSCC through regulating the ATXN1/CPEB3/Notch pathway. These findings provide novel insights for treating and monitoring OSCC.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was conducted with signed informed consent under the approval and guidance of the Ethics Review Board of Chungnam National University Hospital (CNUH-2022-11-004-001). All experiments adhered to the relevant guidelines and regulations of the animal care unit at Chungnam National University. The animal protocols for these experiments received approval from the Ethics Committee of Animal Experimentation of Chungnam National University (No. CNUH-2022-IA0100-00). Consent for publication: Patients agree to participate in this work.

References

    1. Warnakulasuriya S, Kerr AR. Oral Cancer Screening: Past, Present, and Future. J Dent Res. 2021;100:1313–20. - DOI - PubMed
    1. Jadhav KB, Gupta N. Clinicopathological prognostic implicators of oral squamous cell carcinoma: need to understand and revise. N Am J Med Sci. 2013;5:671–9. - DOI - PubMed - PMC
    1. Gandellini P, Giovannetti E, Nicassio F. MicroRNAs in Cancer Management: Big Challenges for Small Molecules. Biomed Res Int. 2015;2015:982156. - DOI - PubMed - PMC
    1. Wang V, Wu W. MicroRNA-based therapeutics for cancer. BioDrugs. 2009;23:15–23. - DOI - PubMed
    1. Piao Y, Jung SN, Lim MA, Oh C, Jin YL, Kim HJ, et al. A circulating microRNA panel as a novel dynamic monitor for oral squamous cell carcinoma. Sci Rep. 2023;13:2000. - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources